Correlation between the consumption of meropenem or doripenem and meropenem susceptibility of Pseudomonas aeruginosa in a University Hospital in Japan

Biological and Pharmaceutical Bulletin

Volumn 35, Issue 6, 2012, Pages 946-949

  Miyawaki, Koji ^a   Miwa, Yoshihiro ^a   Seki, Masafumi ^a   Asari, Seishi ^a   Tomono, Kazunori ^a   Kurokawa, Nobuo ^a  

^a OSAKA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Consumption; Doripenem; Meropenem; Pseudomonas aeruginosa; Susceptibility

Indexed keywords

AMIKACIN; BIAPENEM; CIPROFLOXACIN; DORIPENEM; IMIPENEM; MEROPENEM; PANIPENEM;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM ISOLATION; CROSS RESISTANCE; DRUG USE; HOSPITAL INFECTION; HUMAN; JAPAN; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PSEUDOMONAS AERUGINOSA; UNIVERSITY HOSPITAL;

ANTI-BACTERIAL AGENTS; CARBAPENEMS; CROSS INFECTION; DRUG RESISTANCE, BACTERIAL; DRUG UTILIZATION; HOSPITALS, UNIVERSITY; HUMANS; JAPAN; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 84861903129     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.35.946     Document Type: Article

References (22)

1. Cao B, Wang H, Sun H, Zhu Y, Chen M. Risk factors and clinical outcomes of nosocomial multi-drug resistant Pseudomonas aeruginosa infections. J. Hosp. Infect., 57, 112-118 (2004).
2. Ozkurt Z, Ertek M, Erol S, Altoparlak U, Akcay MN. The risk factors for acquisition of imipenem-resistant Pseudomonas aeruginosa in the burn unit. Burns, 31, 870-873 (2005).
3. Zavascki AP, Cruz RP, Goldani LZ. Risk factors for imipenemresistant Pseudomonas aeruginosa: a comparative analysis of two case-control studies in hospitalized patients. J. Hosp. Infect., 59, 96-101 (2005).
4. Shigemi A, Matsumoto K, Yaji K, Shimodozono Y, Takeda Y, Miyanohara H, Kawamura H, Orita M, Tokuda K, Nishi J, Yamada K. Correlation between meropenem and doripenem use density and the incidence of carbapenem-resistant Pseudomonas aeruginosa. Int. J. Antimicrob. Agents, 34, 589-591 (2009).
5. Meyer E, Schwab F, Gastmeier P, Rueden H, Daschner FD. Surveillance of antimicrobial use and antimicrobial resistance in German intensive care units (SARI): a summary of the data from 2001 through 2004. Infection, 34, 303-309 (2006).
6. Cook PP, Catrou PG, Christie JD, Young PD, Polk RE. Reduction in broad-spectrum antimicrobial use associated with no improvement in hospital antibiogram. J. Antimicrob. Chemother., 53, 853-859 (2004).
7. Sumita Y, Fukasawa M. Meropenem resistance in Pseudomonas aeruginosa. Chemotherapy, 42, 47-56 (1996).
8. Köhler T, Michea-Hamzehpour M, Epp SF, Pechere JC. Carbapenem activities against Pseudomonas aeruginosa: respective contributions of OprD and efflux systems. Antimicrob. Agents Chemother., 43, 424-427 (1999).
9. Livermore DM. Of Pseudomonas, porins, pumps and carbapenems. J. Antimicrob. Chemother., 47, 247-250 (2001).
10. Mushtaq S, Ge Y, Livermore DM. Doripenem versus Pseudomonas aeruginosa in vitro: activity against characterized isolates, mutants, and transconjugants and resistance selection potential. Antimicrob. Agents Chemother., 48, 3086-3092 (2004).
11. Guidelines for ATC classification and DDD assignment 2010. WHO Collaborating Centre for Drug Statistics Methodology, Norwegian Institute of Public Health, Oslo (2009).
12. Miyawaki K, Miwa Y, Tomono K, Kurokawa N. Impact of antimicrobial stewardship by infection control team in a Japanese teaching hospital. Yakugaku Zasshi, 130, 1105-1111 (2010).
13. Hisato A, Miyara T, Moriyama K, Toda H, Yamaguchi T, Matsushima T, Tanaka K, Yoshida R, Takeyama Y. Relation between increase of hand hygiene compliance indexes and decrease of MRSA isolation ratio in a hospital. Jpn. J. Environ. Infect., 26, 243-248 (2011).
14. Takahashi M, Kaneko T, Taira H. Examination of risk factors influencing the detection of carbapenem-resistant Pseudomonas aeruginosa. Jpn. J. Environ. Infect., 25, 104-110 (2010).
15. Kobayashi Y, Norimoto M, Matsushita Y, Jinno Y. Alteration of prescriptions of carbapenems due to pharmacists' intervention in regimen design and the isolation rates of occurrence of imipenemresistant Pseudomonas aeruginosa. J. Jpn. Soc. Hosp. Pharm., 45, 921-924 (2009).
16. Hsueh PR, Chen WH, Luh KT. Relationships between antimicrobial use and antimicrobial resistance in Gram-negative bacteria causing nosocomial infections from 1991-2003 at a university hospital in Taiwan. Int. J. Antimicrob. Agents, 26, 463-472 (2005).
17. Lautenbach E, Weiner MG, Nachamkin I, Bilker WB, Sheridan A, Fishman NO. Imipenem resistance among Pseudomonas aeruginosa isolates: risk factors for infection and impact of resistance on clinical and economic outcomes. Infect. Control Hosp. Epidemiol., 27, 893-900 (2006).
18. Jacoby TS, Kuchenbecker RS, Dos Santos RP, Magedanz L, Guzatto P, Moreira LB. Impact of hospital-wide infection rate, invasive procedures use and antimicrobial consumption on bacterial resistance inside an intensive care unit. J. Hosp. Infect., 75, 23-27 (2010).
19. Sakyo S, Tomita H, Tanimoto K, Fujimoto S, Ike Y. Potency of carbapenems for the prevention of carbapenem-resistant mutants of Pseudomonas aeruginosa: the high potency of a new carbapenem doripenem. J. Antibiot., 59, 220-228 (2006).
20. Tanimoto K, Tomita H, Fujimoto S, Okuzumi K, Ike Y. Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation. Antimicrob. Agents Chemother., 52, 3795-3800 (2008).
21. Credito K, Kosowska-Shick K, Appelbaum PC. Mutant prevention concentrations of four carbapenems against Gram-negative rods. Antimicrob. Agents Chemother., 54, 2692-2695 (2010).
22. Nishio H, Komatsu M, Shibata N, Shimakawa K, Sueyoshi N, Ura T, Satoh K, Toyokawa M, Nakamura T, Wada Y, Orita T, Kofuku T, Yamasaki K, Sakamoto M, Kinoshita S, Aihara M, Arakawa Y. Metallo-β-lactamase-producing Gram-negative bacilli: laboratorybased surveillance in cooperation with 13 clinical laboratories in the Kinki region of Japan. J. Clin. Microbiol., 42, 5256-5263 (2004).